Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KYNU | Q16719 | 1/20 | 0.58 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.50 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.50 |
| ▸ | CTSK | P43235 | 6/20 | 0.49 |
| ▸ | TACR1 | P25103 | 2/20 | 0.49 |
| ▸ | CTSS | P25774 | 4/20 | 0.48 |
| ▸ | CTSL | P07711 | 3/20 | 0.48 |
| ▸ | CTSB | P07858 | 2/20 | 0.48 |
| ▸ | ELANE | P08246 | 1/20 | 0.48 |
| ▸ | PRTN3 | P24158 | 1/20 | 0.47 |
| ▸ | SIRT2 | Q8IXJ6 | 1/20 | 0.46 |
| ▸ | SIRT1 | Q96EB6 | 1/20 | 0.46 |
| ▸ | SIRT3 | Q9NTG7 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21174053 | 1.00 | KYNU (0.58) | KYNUALDH1A1ALOX15CTSKTACR1 | |
| SCHEMBL21174074 | 0.89 | KYNU (0.59) | KYNUALDH1A1ALOX15CTSKTACR1 | |
| SCHEMBL21174075 | 0.89 | KYNU (0.59) | KYNUALDH1A1ALOX15CTSKTACR1 | |
| SCHEMBL21174135 | 0.89 | KYNU (0.59) | KYNUALDH1A1ALOX15CTSKTACR1 | |
| SCHEMBL21174049 | 0.87 | TACR1 (0.53) | KYNUALDH1A1ALOX15CTSKTACR1 | |
| SCHEMBL56432 | 0.87 | TACR1 (0.53) | KYNUALDH1A1ALOX15CTSKTACR1 | |
| SCHEMBL21174062 | 0.87 | TACR1 (0.53) | KYNUALDH1A1ALOX15CTSKTACR1 | |
| SCHEMBL57804 | 0.87 | KYNU (0.48) | KYNUALDH1A1ALOX15CTSKTACR1 | |
| SCHEMBL57114 | 0.87 | ATM (0.55) | KYNUALDH1A1ALOX15CTSKCTSS | |
| SCHEMBL57134 | 0.85 | POLB (0.48) | KYNUALDH1A1CTSKTACR1CTSS |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10774098-B2 | Nahlsgen optical resolution method | KYOTO UNIVERSITY (JP) | 2020-09-15 | — | — | US | disclosed |
| US-20190225634-A1 | NAHLSGEN OPTICAL RESOLUTION METHOD | KYOTO UNIVERSITY (JP) | 2019-07-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10774098-B2 | Nahlsgen optical resolution method | HACL2, HAO2, HPD | KYNU 1549/4885ALDH1A1 150/4885ALOX15 1768/4885 |
| US-20190225634-A1 | NAHLSGEN OPTICAL RESOLUTION METHOD | HACL2, HAO2, HPD | KYNU 1549/4885ALDH1A1 150/4885ALOX15 1768/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.